FDA approves H. pylori breath test for children

The US Food & Drug Administration has approved the first breath test for use in children ranging in age between 3 and 17 for the detection of the Helicobacter pylori bacterial infection.

BreathTek UBT was first FDA approved for adults back in 1996. It was approved for children based on a published study involving 176 patients. The detector proved to have a 95.8 percent sensitivity rating.

In addition to being a culprit in causing gastritis and ulcers in the stomach, theHelicobacter pyloribacteria has also been implicated in some stomach cancers, notably in mucosal-associated-lymphoid-type (MALT) lymphoma, a mostly indolent for of B-lineage non-Hodgkin's lymphoma.

Source: FDA

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap